PMID- 35869807
OWN - NLM
STAT- MEDLINE
DCOM- 20220824
LR  - 20231211
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 56
IP  - 6
DP  - 2022 Sep
TI  - Real-world experience of switching from intravenous to subcutaneous vedolizumab 
      maintenance treatment for inflammatory bowel diseases.
PG  - 1044-1054
LID - 10.1111/apt.17153 [doi]
AB  - BACKGROUND: Subcutaneous (SC) vedolizumab is effective in inflammatory bowel 
      diseases (IBD) when administered after induction with two infusions. AIM: To 
      assess the effectiveness, safety and pharmacokinetics of a switch from 
      intravenous (IV) to SC maintenance vedolizumab in patients with IBD METHODS: In 
      this prospective cohort study, patients with IBD who had >/=4 months IV vedolizumab 
      were switched to SC vedolizumab. We studied the time to discontinuation of SC 
      vedolizumab, adverse events (AEs), changes in clinical and biochemical outcomes 
      and vedolizumab concentrations at baseline, and weeks 12 and 24. RESULTS: We 
      included 82 patients with Crohn's disease (CD) and 53 with ulcerative colitis 
      (UC). Eleven (13.4%) patients with CD and five (9.4%) with UC discontinued SC 
      vedolizumab after a median of 18 (IQR 8-22) and 6 weeks (IQR 5-10), respectively. 
      Four patients with CD switched to a different drug due to loss of response, nine 
      switched back to IV vedolizumab due to adverse events, and three due to needle 
      fear. Common AEs were injection site reactions (n = 15) and headache (n = 6). 
      Median clinical and biochemical disease activity remained stable after the 
      switch. Median serum vedolizumab concentrations increased from 19 mug/ml at the 
      time of the switch to 31 mug/ml 12 weeks after the switch (p < 0.005). 
      CONCLUSIONS: Switching from IV to SC vedolizumab maintenance treatment is 
      effective in patients with CD or UC. However, 9% of patients were switched back 
      to IV vedolizumab due to adverse events or fear of needles.
CI  - (c) 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John 
      Wiley & Sons Ltd.
FAU - Volkers, Adriaan
AU  - Volkers A
AUID- ORCID: 0000-0002-9547-1627
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - Straatmijer, Tessa
AU  - Straatmijer T
AUID- ORCID: 0000-0001-6989-5226
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
AD  - Department of Gastroenterology and Hepatology, Leiden University Medical Centre, 
      Leiden, The Netherlands.
FAU - Duijvestein, Marjolijn
AU  - Duijvestein M
AD  - Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - Sales, Amber
AU  - Sales A
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - Levran, Amit
AU  - Levran A
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - van Schaik, Fiona
AU  - van Schaik F
AD  - University Medical Centre Utrecht, Utrecht, The Netherlands.
FAU - Maljaars, Jeroen
AU  - Maljaars J
AUID- ORCID: 0000-0003-0477-9499
AD  - Department of Gastroenterology and Hepatology, Leiden University Medical Centre, 
      Leiden, The Netherlands.
FAU - Gecse, Krisztina
AU  - Gecse K
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - Ponsioen, Cyriel
AU  - Ponsioen C
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - Grootjans, Joep
AU  - Grootjans J
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - Hanzel, Jurij
AU  - Hanzel J
AUID- ORCID: 0000-0003-3158-8014
AD  - Department of Gastroenterology, UMC Ljubljana, Faculty of Medicine, University of 
      Ljubljana, Ljubljana, Slovenia.
FAU - Tack, Greetje
AU  - Tack G
AD  - Medical centre Leeuwarden, Leeuwarden, The Netherlands.
FAU - Jansen, Jeroen
AU  - Jansen J
AD  - OLVG, Amsterdam, The Netherlands.
FAU - Hoentjen, Frank
AU  - Hoentjen F
AUID- ORCID: 0000-0001-5314-4452
AD  - Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
AD  - Division of Gastroenterology, Department of Medicine, University of Alberta, 
      Edmonton, Canada.
FAU - de Boer, Nanne
AU  - de Boer N
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, 
      Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
FAU - van der Marel, Sander
AU  - van der Marel S
AD  - Haaglanden Medical Centre, The Hague, The Netherlands.
FAU - Dijkstra, Gerard
AU  - Dijkstra G
AD  - University Medical Centre Groningen, University of Groningen, Groningen, The 
      Netherlands.
FAU - Oldenburg, Bas
AU  - Oldenburg B
AD  - University Medical Centre Utrecht, Utrecht, The Netherlands.
FAU - Lowenberg, Mark
AU  - Lowenberg M
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - van der Meulen, Andrea
AU  - van der Meulen A
AD  - Department of Gastroenterology and Hepatology, Leiden University Medical Centre, 
      Leiden, The Netherlands.
FAU - D Haens, Geert
AU  - D Haens G
AD  - Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology 
      Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
CN  - IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220723
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Gastrointestinal Agents)
RN  - 9RV78Q2002 (vedolizumab)
RN  - Belonephobia
SB  - IM
CIN - Aliment Pharmacol Ther. 2023 Mar;57(6):741-742. PMID: 36821749
CIN - Aliment Pharmacol Ther. 2023 Mar;57(6):743-744. PMID: 36821751
CIN - Aliment Pharmacol Ther. 2023 Jul;58(2):262-263. PMID: 37352154
MH  - Antibodies, Monoclonal, Humanized
MH  - *Colitis, Ulcerative/chemically induced/drug therapy
MH  - *Crohn Disease/chemically induced/drug therapy
MH  - Gastrointestinal Agents/therapeutic use
MH  - Humans
MH  - *Inflammatory Bowel Diseases/drug therapy
MH  - Phobic Disorders
MH  - Prospective Studies
MH  - Remission Induction
MH  - Treatment Outcome
PMC - PMC9540102
OTO - NOTNLM
OT  - inflammatory bowel disease
OT  - real-world evidence
OT  - subcutaneous vedolizumab
COIS- A.V., T.S., A.S., A.L.: none. M.D.: reports advisory fees from Echo Pharma and 
      Robarts Clinical Trials, Inc., speaker fees from Janssen, Merck & Co., Inc., 
      Pfizer, Takeda and Tillotts Pharma, and nonfinancial support from Dr. Falk Pharm. 
      F.S: Advisory Boards Takeda, Galapagos. K.G.: has received grants from Pfizer 
      Inc. and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, 
      Galapagos, Gilead, ImmunicTherapeutics, Janssen Pharmaceuticals, Novartis, Pfizer 
      Inc., Samsung Bioepis and Takeda; and speaker's honoraria from Celltrion, 
      Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis, Takeda 
      and Tillotts. C.P.: received grants or contracts from Takeda, Pliant, and Gilead 
      Sciences; consulting fees from Pliant and Shire (Takeda); and payment or 
      honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or 
      educational events from Takeda, Tillotts Pharma, and Pfizer outside of the 
      submitted work. J.G.: has served as a speaker for: Dr. Falk, GlaxoSmithKline, 
      Janssen-Cilag. J.H.: speaker's fees from Abbvie, Janssen, Takeda; consulting fees 
      from Alimentiv Inc. G.T.: none. J.J.: has served on advisory boards and as a 
      speaker or consultant for Abbvie, Amgen, Ferring, Fresenius, Janssen, MSD, 
      Pfizer, Takeda. A.G.L. F.H.: Frank Hoentjen has served on advisory boards and as 
      a speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr 
      Falk Funding (Grants/Honoraria): Takeda, Janssen-Cilag, Abbvie Consulting Fees: 
      Celgene. N.B.: has served as a speaker for AbbVie and MSD and has served as a 
      consultant and/or principal investigator for TEVA Pharma BV and Takeda. He has 
      received a [unrestricted] research grant from Dr. Falk, TEVA Pharma BV, MLDS and 
      Takeda. All outside the submitted work. G.Dijkstra.: has received speakers fees 
      from Janssen-Cilag, Pfizer, Takeda and Abbvie. B.O.: has served as speaker for 
      Galapagos, MSD, Janssen and received unrestricted grants from Takeda, Pfizer, 
      Galapagos, Ferring, Celltrion and Abbvie. M.L.: has served as a speaker and/or 
      principal investigator for: Abbvie, Alimentiv, Bristol Myers Squibb, Celgene, 
      Covidien, Dr. Falk, Ferring Pharmaceuticals, Galapagos, Gilead, GlaxoSmithKline, 
      Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, 
      Takeda, Tillotts, Tramedico. He has received research grants from AbbVie, Merck 
      Sharp & Dohme, Dr Falk, Achmea healthcare, Galapagos and ZonMW. A.M.: has served 
      as speaker for: Galapagos, Janssen-Cilag, Takeda, Tramedico. She has received 
      research grants from Cablon, Galapagos, Nestle, Norgine and ZonMW. G.D.: 
      Consultancy for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena 
      Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli 
      Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, 
      Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson 
      and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, 
      Prometheus Biosciences, Progenity, Protagonist. Speaker's bureau for Abbvie, 
      Arena, Galapagos, Gilead, Pfizer, BMS, Takeda.
EDAT- 2022/07/24 06:00
MHDA- 2022/08/25 06:00
PMCR- 2022/10/07
CRDT- 2022/07/23 05:03
PHST- 2022/05/16 00:00 [revised]
PHST- 2022/04/26 00:00 [received]
PHST- 2022/07/07 00:00 [accepted]
PHST- 2022/07/24 06:00 [pubmed]
PHST- 2022/08/25 06:00 [medline]
PHST- 2022/07/23 05:03 [entrez]
PHST- 2022/10/07 00:00 [pmc-release]
AID - APT17153 [pii]
AID - 10.1111/apt.17153 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. doi: 10.1111/apt.17153. Epub 
      2022 Jul 23.